Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK2 | P24941 | 7/20 | 0.48 |
| ▸ | MAPT | P10636 | 4/20 | 0.44 |
| ▸ | SMARCA2 | P51531 | 1/20 | 0.44 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.44 |
| ▸ | HTR6 | P50406 | 3/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3355292 | 0.87 | HTR6 (0.59) | CDK2MAPTRXFP1HTR6MEN1 | |
| SCHEMBL9400557 | 0.84 | MAPT (0.51) | CDK2MAPTMEN1LMNAKMT2A | |
| SCHEMBL3354579 | 0.79 | MAPT (0.47) | CDK2MAPTHTR6MEN1LMNA | |
| SCHEMBL29540778 | 0.79 | MAPT (0.53) | CDK2MAPTMEN1LMNAKMT2A | |
| SCHEMBL12608632 | 0.78 | MAPT (0.63) | MAPTSMARCA2RXFP1MEN1LMNA | |
| SCHEMBL3352349 | 0.78 | HTR6 (0.50) | MAPTHTR6MEN1KMT2A | |
| SCHEMBL3355596 | 0.78 | ALDH1A1 (0.55) | CDK2MAPTHTR6MEN1LMNA | |
| SCHEMBL3355597 | 0.77 | ALDH1A1 (0.57) | CDK2HTR6MEN1LMNAKMT2A | |
| SCHEMBL3351522 | 0.77 | HTR6 (0.51) | CDK2HTR6MEN1LMNAKMT2A | |
| SCHEMBL12608626 | 0.75 | MAPT (0.56) | MAPTSMARCA2RXFP1MEN1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2141163-A1 | Substituted thiazolidinones, their production and utilisation as medicine | Bayer Schering Pharma AG (DE) | 2010-01-06 | — | — | EP | disclosed |